Eylea

Aflibercept, the active ingredient in Eylea, is a VEGF inhibitor presented as a 40 mg/ml solution for intravitreal use. It is used to treat various eye conditions in adults, including neovascular age-related macular degeneration, macular edema secondary to retinal vein occlusion, diabetic macular edema, and neovascularization associated with pathological myopia. GNH USA supplies Eylea as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies, and clinics worldwide.

Eylea is administered as an intravitreal injection and is designed to block the activity of vascular endothelial growth factor (VEGF) and placental growth factor (PlGF), which are involved in the formation of new blood vessels in the eye. This helps to stabilize and, in many cases, improve vision loss related to the treated conditions.

Eylea is used to treat various eye conditions by inhibiting the growth of abnormal blood vessels in the eye. It is indicated for the following conditions:

- Neovascular (wet) age-related macular degeneration (AMD): Helps to stabilize and improve vision loss related to the condition. - Macular edema secondary to retinal vein occlusion (RVO): Reduces swelling in the macula caused by blocked blood vessels, improving central vision. - Diabetic macular edema (DME): Treats swelling in the retina due to fluid leakage from blood vessels in diabetic patients, improving central vision. - Neovascularization associated with pathological myopia: Prevents the formation of new blood vessels that can lead to vision loss in individuals with severe nearsightedness.

Eylea, like all medications, can cause side effects. Common side effects include:

Common Side Effects: - Eye pain or redness at the injection site. - Floaters or flashes of light in the vision. - Increased intraocular pressure. - Conjunctival hemorrhage. - Cataracts. - Vitreous detachment.

Serious or Rare Side Effects: - Endophthalmitis (severe eye infection). - Retinal detachment. - Uveitis (inflammation of the eye). - Increased risk of arterial thromboembolic events (e.g., heart attack or stroke). - Severe allergic reactions.

Eylea should be used with caution and under the supervision of a healthcare professional. Precautions include:

- Infection risk: The injection site must be kept clean to prevent infection. - Eye inflammation: Patients with active intraocular inflammation should be monitored closely. - Arterial thromboembolic events: Patients with a history of cardiovascular disease should be carefully evaluated. - Pregnancy: Women with potential for pregnancy should use effective contraception during treatment and for at least 3 months after the last injection. - Storage: Store at 2-8°C: Keep refrigerated, protect from light, do not freeze or shake.

Eylea may interact with other medications, and these interactions should be carefully managed:

Major Interactions (Avoid): - Other anti-VEGF agents: Concurrent use may increase the risk of adverse effects. - Immunosuppressants: May enhance the risk of infections. - Anticoagulants: Increased risk of bleeding events.

Moderate Interactions (Monitor Closely): - Corticosteroids: May increase the risk of cataracts and glaucoma. - Nonsteroidal anti-inflammatory drugs (NSAIDs): May increase the risk of bleeding. - Antiplatelet agents: May enhance the risk of bleeding.